Insights into pet-based radiogenomics in oncology: an updated systematic review DOI Creative Commons
Luca Filippi, Luca Urso, Luigi Manco

и другие.

European Journal of Nuclear Medicine and Molecular Imaging, Год журнала: 2025, Номер unknown

Опубликована: Апрель 7, 2025

Abstract Purpose This study systematically reviews current evidence on radiogenomics applied to positron emission tomography (PET) imaging across oncological diseases. The primary objective is evaluate how PET-based aids in understanding tumor biology, prognostic stratification, and clinical outcome prediction, while identifying methodological challenges the field. Methods A systematic review was conducted following PRISMA guidelines, focusing English-language studies indexed Scopus, PubMed, Web of Science until October 31, 2024. Inclusion criteria targeted original research articles involving human oncology using radiomics genomics a comprehensive “omics” framework. Data extraction included patient cohorts, radiopharmaceuticals statistical methods. Studies were assessed for rigor reporting quality according scores (RQS 2.0). Results Eighteen 1780 patients included, with 75.8% focused lung cancer. Most retrospective (72.2%) single-center (77.7%). radiopharmaceutical [ 18 F]FDG (88.8%). Key findings demonstrated correlations between PET-derived radiomic features genomic alterations, such as KRAS, EGFR, TGFβ mutations cancer, biomarkers other malignancies. However, systemic shortcomings, including limited external validation, low reproducibility, inadequate harmonization, prevalent. None exceeded 50% RQS maximum score. Conclusion holds significant potential advancing precision by capturing heterogeneity improving stratification. limitations, particularly regarding design data transparency, hinder its applicability. Future should prioritize multicentric designs, robust validations, enhanced standardization fully realize discipline’s potential.

Язык: Английский

Insights into pet-based radiogenomics in oncology: an updated systematic review DOI Creative Commons
Luca Filippi, Luca Urso, Luigi Manco

и другие.

European Journal of Nuclear Medicine and Molecular Imaging, Год журнала: 2025, Номер unknown

Опубликована: Апрель 7, 2025

Abstract Purpose This study systematically reviews current evidence on radiogenomics applied to positron emission tomography (PET) imaging across oncological diseases. The primary objective is evaluate how PET-based aids in understanding tumor biology, prognostic stratification, and clinical outcome prediction, while identifying methodological challenges the field. Methods A systematic review was conducted following PRISMA guidelines, focusing English-language studies indexed Scopus, PubMed, Web of Science until October 31, 2024. Inclusion criteria targeted original research articles involving human oncology using radiomics genomics a comprehensive “omics” framework. Data extraction included patient cohorts, radiopharmaceuticals statistical methods. Studies were assessed for rigor reporting quality according scores (RQS 2.0). Results Eighteen 1780 patients included, with 75.8% focused lung cancer. Most retrospective (72.2%) single-center (77.7%). radiopharmaceutical [ 18 F]FDG (88.8%). Key findings demonstrated correlations between PET-derived radiomic features genomic alterations, such as KRAS, EGFR, TGFβ mutations cancer, biomarkers other malignancies. However, systemic shortcomings, including limited external validation, low reproducibility, inadequate harmonization, prevalent. None exceeded 50% RQS maximum score. Conclusion holds significant potential advancing precision by capturing heterogeneity improving stratification. limitations, particularly regarding design data transparency, hinder its applicability. Future should prioritize multicentric designs, robust validations, enhanced standardization fully realize discipline’s potential.

Язык: Английский

Процитировано

0